- Home
- YXT vs SCPH Comparison
YXT vs SCPH Comparison
Compare YXT & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- SCPH
- Stock Information
- Founded
- YXT 2011
- SCPH 2013
- Country
- YXT China
- SCPH United States
- Employees
- YXT N/A
- SCPH N/A
- Industry
- YXT
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- YXT
- SCPH Health Care
- Exchange
- YXT NYSE
- SCPH Nasdaq
- Market Cap
- YXT 268.5M
- SCPH 274.7M
- IPO Year
- YXT 2024
- SCPH 2017
- Fundamental
- Price
- YXT $2.15
- SCPH $4.21
- Analyst Decision
- YXT
- SCPH Strong Buy
- Analyst Count
- YXT 0
- SCPH 1
- Target Price
- YXT N/A
- SCPH $18.00
- AVG Volume (30 Days)
- YXT 20.9K
- SCPH 175.2K
- Earning Date
- YXT 11-21-2024
- SCPH 11-19-2024
- Dividend Yield
- YXT N/A
- SCPH N/A
- EPS Growth
- YXT N/A
- SCPH N/A
- EPS
- YXT N/A
- SCPH N/A
- Revenue
- YXT $53,329,409.00
- SCPH $24,048,000.00
- Revenue This Year
- YXT N/A
- SCPH $195.62
- Revenue Next Year
- YXT N/A
- SCPH $145.07
- P/E Ratio
- YXT N/A
- SCPH N/A
- Revenue Growth
- YXT N/A
- SCPH 549.77
- 52 Week Low
- YXT $2.05
- SCPH $3.24
- 52 Week High
- YXT $11.00
- SCPH $6.71
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- SCPH 45.44
- Support Level
- YXT N/A
- SCPH $4.00
- Resistance Level
- YXT N/A
- SCPH $4.60
- Average True Range (ATR)
- YXT 0.00
- SCPH 0.22
- MACD
- YXT 0.00
- SCPH 0.02
- Stochastic Oscillator
- YXT 0.00
- SCPH 34.17
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.